Introduction
Since the beginning of anti-covid-19 vaccination campaigns in different
countries, more frequent and stronger adverse effects of mRNA vaccines
were reported in subjects having been already infected with SARS-Cov-2,
than in naïve individuals (1-3). Generally, such patients experienced
amplified systemic adverse effects, such as fatigue, headache, chills,
fever, and muscle or joint pains. However, information is lacking in
patients having suffered and recovered from more or less severe forms of
covid-19. The present clinical history highlights an unusual strong
reactivation of a pulmonary pathology beginning some hours after the
administration of a first dose of the BNT162b2 mRNA vaccine in a patient
having presented a symptomatic pulmonary form of covid-19 one month
before. The lessons of this clinical history in terms of consequences
for the continuation of vaccination campaigns in previously infected
patients, as well as the possible mechanisms involved are discussed.